<DOC>
	<DOCNO>NCT00595985</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability sorafenib second line treatment patient Advanced Metastatic Gastric Cancer ( A/MGC ) .</brief_summary>
	<brief_title>Sorafenib Second Line Treatment Patients With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>Up , although FU base , cisplatin base taxane base regimen , ECF regimen suggest first line therapy A/MGC FDA , standard regimen patient A/MGC second line treatment . Based promising result sorafenib primary hepatic carcinoma renal cancer , design clinical trial evaluate efficacy , time progression overall survival sorafenib A/MGC patient second line treatment .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm advanced metastatic adenocarcinoma stomach ECOG performance scale ≤ 2 At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Adequate hepatic , renal , heart , hematologic function : platelets＞80 × 109/L neutrophil＞2.0 × 109/L serum creatinine ≤ 1.5mg/dl total bilirubin within upper limit normal ( ULN ) serum transaminase ≤ 2.5 × ULN Pregnant lactate woman Concurrent cancer History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Neuropathy , brain , leptomeningeal involvement Uncontrolled significant comorbid condition previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Time Progression</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Response rate</keyword>
	<keyword>Quality live</keyword>
	<keyword>Toxicities</keyword>
</DOC>